{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:46:43Z","timestamp":1792057603576,"version":"4.4.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Switching strategy with bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) has become a gold standard for people living with HIV (PLWH), achieving high efficacy and safety rates. However, data regarding immune status in long-term real-life cohorts of pretreated patients are needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a multicentre, non-controlled, retrospective study in virologically suppressed PLWH switching to B\/F\/TAF. We evaluated CD4+, CD8+ and CD4+\/CD8+ ratio, efficacy and safety at weeks 48 and 96.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study comprised 1966 PLWH from 12 hospitals in Spain, of whom 80% were men, and the median age was 51.0 [42.0\u201357.0] years. The median time of HIV infection was 18.0 [10.0\u201327.0] years. No significant changes in CD4+, CD8+ T cells, or CD4+\/CD8+ were observed after 96\u2005weeks. Nevertheless, in women at weeks 48 and 96, we found a significant increase of CD4+ T cells and a significant decrease in CD8+ T cells. In patients \u226560\u2005years at week 96, CD4 T cells significantly increased and CD8+ T cells significantly decreased at week 48. The on-treatment analysis revealed HIV-RNA &amp;lt;50\u2005copies\/mL in 95.6% (1700\/1779) and 96.7% (1312\/1356) of patients at weeks 48 and 96, respectively. The rates increased to 99.2% (1765\/1779) and 99.7% (1352\/1356) when considering HIV-RNA &amp;lt;200\u2005copies\/mL. No resistance mutations were detected in virologic failures. B\/F\/TAF discontinuations accounted for 10.2% (200). Simplification was the most common reason for discontinuation in 3.8% (74) of patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In long-term virologically controlled PLWH, B\/F\/TAF achieved high efficacy rates and slightly improved immune status in women and individuals aged 60 and over after 48 and 96 of switching.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae011","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T02:46:07Z","timestamp":1706150767000},"page":"595-607","source":"Crossref","is-referenced-by-count":12,"title":["Real-life data of immune recovery using bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48\u201396\u2005weeks of RETROBIC Study"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7323-114X","authenticated-orcid":false,"given":"Jes\u00fas","family":"Troya","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Infanta Leonor , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Pousada","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital \u00c1lvaro Cunqueiro , Vigo , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Mic\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario La Paz , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Galera","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Virgen de la Arrixaca , Murcia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Sanz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Pr\u00edncipe de Asturias , Alcal\u00e1 de Henares , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"de los Santos","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario La Princesa , Madrid , Spain"},{"name":"CIBERINFEC Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Due\u00f1as","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednico Universitario de Valladolid , Valladolid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Cabello","sequence":"additional","affiliation":[{"name":"Department of Infectiosu Diseases, Hospital Cl\u00ednico San Carlos , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Complejo Asistencial de Zamora , Zamora , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Josefa","family":"Galindo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednico de Valencia , Valencia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Garcinu\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Complejo Asistencial de \u00c1vila , \u00c1vila , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pedrero-Tom\u00e9","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n de Investigaci\u00f3n e Innovaci\u00f3n Hospital Universitario Infanta Leonor , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4847-8014","authenticated-orcid":false,"given":"Luis","family":"Buz\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital de Burgos , Burgos , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"2024020615320849300_dkae011-B1","author":"European AIDS Clinical Society"},{"key":"2024020615320849300_dkae011-B2"},{"key":"2024020615320849300_dkae011-B3","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2024020615320849300_dkae011-B4","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2024020615320849300_dkae011-B5","doi-asserted-by":"crossref","first-page":"101991","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2024020615320849300_dkae011-B6","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-380 blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2024020615320849300_dkae011-B7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2024020615320849300_dkae011-B8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s12879-020-05240-y","article-title":"A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to bictegravir\/emtricitabine\/tenofovir alafenamide single tablet regimen in integrase inhibitor-na\u00efve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial","volume":"20","author":"Iwuji","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2024020615320849300_dkae011-B9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40121-021-00449-z","article-title":"Meta-analysis of efficacy and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide among people living with HIV","volume":"10","author":"Chen","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2024020615320849300_dkae011-B10","author":"Gilead Sciences"},{"key":"2024020615320849300_dkae011-B11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/QAI.0000000000002747","article-title":"Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil fumarate","volume":"88","author":"Campbell","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024020615320849300_dkae011-B12","article-title":"Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety","author":"Chan","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2024020615320849300_dkae011-B13","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkab481","article-title":"Real-life experience with bictegravir\/emtricitabine\/tenofovir alafenamide in a large reference clinical centre","volume":"77","author":"Ambrosioni","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024020615320849300_dkae011-B14","doi-asserted-by":"crossref","first-page":"e27330","DOI":"10.1097\/MD.0000000000027330","article-title":"Real-world efficacy and safety of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in older people living with HIV","volume":"100","author":"Rolle","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2024020615320849300_dkae011-B15","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/biomedicines10081823","article-title":"Viro-immunological, clinical outcomes and costs of switching to BIC\/TAF\/FTC in a cohort of people living with HIV: a 48-week prospective analysis","volume":"10","author":"Mazzitelli","year":"2022","journal-title":"Biomedicines"},{"key":"2024020615320849300_dkae011-B16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2024020615320849300_dkae011-B17","author":"World Health Organization"},{"key":"2024020615320849300_dkae011-B18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0000000000002266","article-title":"Immunological and virological responses in older HIV-infected adults receiving antiretroviral therapy: an evidence-based meta-analysis","volume":"83","author":"Zhang","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024020615320849300_dkae011-B19","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1097\/00002030-200410210-00007","article-title":"Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French hospital database on HIV","volume":"18","author":"Grabar","year":"2004","journal-title":"AIDS"},{"key":"2024020615320849300_dkae011-B20","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3390\/v15061222","article-title":"Immune reconstitution and safe metabolic profile after the switch to bictegravir\/emtricitabine\/tenofovir alafenamide fumarate among virologically controlled PLWH: a 96 week update from the BICTEL cohort","volume":"15","author":"Lazzaro","year":"2023","journal-title":"Viruses"},{"key":"2024020615320849300_dkae011-B21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hiv.13319","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people \u226565 years of age","volume":"24","author":"Maggiolo","year":"2023","journal-title":"HIV Med"},{"key":"2024020615320849300_dkae011-B22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12981-018-0200-4","article-title":"CD4\/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV","volume":"15","author":"Han","year":"2018","journal-title":"AIDS Res Ther"},{"key":"2024020615320849300_dkae011-B23","doi-asserted-by":"crossref","first-page":"104072","DOI":"10.1016\/j.ebiom.2022.104072","article-title":"Predictive value of CD8+ T cell and CD4\/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events","volume":"80","author":"Serrano-Villar","year":"2022","journal-title":"EBioMedicine"},{"key":"2024020615320849300_dkae011-B24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAI.0000000000002137","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial","volume":"82","author":"Kityo","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024020615320849300_dkae011-B25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.37201\/req\/013.2022","article-title":"Eficacia en vida real del cambio a bictegravir\/emtricitabina\/tenofovir alafenamida en pacientes previamente tratados con pautas triples que contienen rilpivirina [real-world efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine]","volume":"35","author":"de Gea Grela","year":"2022","journal-title":"Rev Esp Quimioter"},{"key":"2024020615320849300_dkae011-B26","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024020615320849300_dkae011-B27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/QAI.0000000000002454","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) from dolutegravir (DTG)+F\/TAF or DTG+ F\/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance","volume":"85","author":"Acosta","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024020615320849300_dkae011-B28","doi-asserted-by":"crossref","first-page":"ofad257","DOI":"10.1093\/ofid\/ofad257","article-title":"Risk of HIV viral rebound in the era of universal treatment in a multicenter sample of persons with HIV in primary care","volume":"10","author":"Liu","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024020615320849300_dkae011-B29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/PPA.S340621","article-title":"Polypharmacy, medication-related burden and antiretroviral therapy adherence in people living with HIV aged 50 and above: a cross-sectional study in Hunan, China","volume":"16","author":"Zheng","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"2024020615320849300_dkae011-B30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors","volume":"33","author":"Eckard","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2024020615320849300_dkae011-B31","doi-asserted-by":"crossref","first-page":"101412","DOI":"10.1016\/j.eclinm.2022.101412","article-title":"Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy-a systematic literature review and network meta-analysis","volume":"48","author":"Kanters","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2024020615320849300_dkae011-B32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/03007995.2023.2239661","article-title":"Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims","volume":"39","author":"Tse","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"2024020615320849300_dkae011-B33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0000000000002853","article-title":"Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV","volume":"35","author":"Guaraldi","year":"2021","journal-title":"AIDS"},{"key":"2024020615320849300_dkae011-B34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/aid.2022.0130","article-title":"Weight gain after 12 months of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed HIV patients","volume":"39","author":"P\u00e9rez-Barrag\u00e1n","year":"2023","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/3\/595\/58681866\/dkae011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/3\/595\/58681866\/dkae011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:09:56Z","timestamp":1722298196000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/3\/595\/7588673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,24]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae011","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,1,24]]}}}